Who are Tavalisse's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ofev.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fostamatinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tavalisse — Competitive Intelligence Brief

Tavalisse (FOSTAMATINIB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Receptor-type tyrosine-protein kinase FLT3 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Tavalisse (FOSTAMATINIB) — Rigel Pharms. Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tavalisse TARGET	FOSTAMATINIB	Rigel Pharms	marketed		Receptor-type tyrosine-protein kinase FLT3	2018-01-01
Ofev	NINTEDANIB	Boehringer Ingelheim	marketed	Kinase Inhibitor	Receptor-type tyrosine-protein kinase FLT3	2014-01-01

Recent regulatory actions (last 90 days)

2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · MOH · likely_approved · IL · Boehringer Ingelheim
2026-04-02 — Ofev · HSA · likely_approved · SG · Boehringer Ingelheim
2026-04-02 — Ofev · SFDA · likely_approved · SA · Boehringer Ingelheim
2026-04-02 — Ofev · MOH · likely_approved · AE · Boehringer Ingelheim
2026-04-02 — Ofev · MFDS · likely_approved · KR · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tavalisse — Competitive Intelligence Brief. https://druglandscape.com/ci/fostamatinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab